Bertis Inc.
Address : 3rd floor, B Building, 33, Gwacheon-daero 7-gil, Gwacheon-si, Gyeonggi-do, Republic of Korea
General : contact@bertis.comIR : ir@bertis.comMedia : communication@bertis.com
NEWSROOM
Read latest news from Bertis
Bertis, Successful in Clinical Proteomics Technology Commercialization, Seeks International Business Partners at BIO USA 2024
Date 2024.05.28 Hit 1,831 News |
---|
Bertis, Successful in Clinical Proteomics Technology Commercialization, Seeks International Business Partners at BIO USA 2024
- Participating in the world's largest bio conference, hosted by the Biotechnology Innovation Organization (BIO), from June 3-6 to explore business development opportunities with global bio and pharmaceutical companies. - Aiming to secure international business partners for proteomics-based early diagnostic tests through the 'Seoul Bio Forum' on June 3 and the 'Company Presentation' on June 5. On May 28th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced that it will participate in the world's largest bio conference, the 'BIO International Convention 2024' (BIO USA 2024), held at the San Diego Convention Center in the United States from June 3 to 6. At BIO USA 2024, where leading companies, research institutions, and investors from the global bio industry will gather, Bertis will conduct two company presentations. These presentations will highlight advancements in clinical proteomics technology and share the latest research developments and business achievements of Bertis, including their successfully commercialized proteomics-based early diagnostic test. Through these activities, Bertis aims to explore various business development opportunities with global bio and pharmaceutical companies. [Image] Bertis Bio USA 2024 Presentation Schedule The first company introduction presentation will take place on June 3rd, local time (PST), at 6:00 PM at the Aquillius Innovation Hub as part of the 'Seoul Bio Forum,' organized by Invest Seoul, Seoul BioHub, and others. The event is dedicated to fostering networking opportunities among Korean enterprises engaged in BIO USA 2024, venture capital firms seeking U.S. market entry and investment, and bio-tech and legal entities possessing the requisite expertise for U.S. expansion. Bertis will showcase its proteomics-based early diagnosis solution technology and outline its growth strategy. On the third day of the event, June 5th at 2:30 PM, Bertis will conduct a Company Presentation session at Hall A Company Presentation Theater4. During this session, Bertis will introduce its successfully commercialized proteomics-based early diagnostic blood test pipeline and its mass spectrometry-based omics analysis service PASS (Pan-omics Analysis Service & Solution) to global bio-pharmaceutical companies. The company aims to explore opportunities for overseas business partnerships and collaborations through this session. Seung-man Han, the CEO of Bertis, stated, "Proteomics will play a crucial role in addressing major challenges facing the medical and healthcare sectors worldwide, enabling precision medicine. Through this event, Bertis aims to share the excellence and commercial viability of our core technology. We also strive to secure business cooperation opportunities to accelerate the introduction of proteomics-based technologies and products into clinical practice." Furthermore, Bertis leads technological innovation in the field of clinical proteomics by leveraging ProteoID, its core technology framework spanning protein data analysis to product and service commercialization. In 2019, Bertis achieved the world's first commercialization of a proteomics-based early diagnostic blood test for breast cancer, MASTOCHECK®, in both domestic and Singaporean markets, conducting a cumulative total of 170,000 tests in South Korea. Currently, they are advancing the development of early diagnostic tests for pancreatic and ovarian cancers as part of their pipeline expansion. |